FDA accepts for filing new drug application for tivozanib as a treatment of relapsed or refractory renal cell carcinoma

The submission for this oral, once-daily, next-generation VEGFR tyrosine kinase inhibitor is based on phase 3 study, TIVO-3 comparing tivozanib to sorafenib in 3rd or 4th line treatment setting. It is currently licensed as a first line treatment or second line in certain patients

Biospace Inc.